Specialty Pharmacy

The effect of oral androgen signaling inhibitor therapies on patients with pre-existing cardiovascular disease may increase the risk of death.

Top news of the day from across the health care landscape.

An upcoming webinar by Trellis Rx on Wednesday, September 18, will offer a firsthand look into how to accelerate the growth of your specialty pharmacy program by building strong provider partnerships.

An in-house specialty pharmacy can provide significant financial gain for health systems by preventing revenue from being diverted to outside pharmacies.

Selinexor with dexamethasone effective in more than one-quarter of patients with multiple myeloma during a clinical trial.

Top news of the day from across the health care landscape.

Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL is now approved for the treatment of active ankylosing spondylitis.

Patients with progressive multiple sclerosis who were placed on the Wahls diet, which is high in fruits and vegetables, found to experience improved fatigue levels.

The findings showed a potential immune biomarker that may help predict patient response to standard-of-care treatment sorafenib for advanced liver cancer.

Top news of the day from across the health care landscape.

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.

Top news of the day from across the health care landscape.

A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.

Top news of the day from across the health care landscape.

Novel process may identify cancer metastasis at an earlier stage when it may be easier to treat.

Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.

Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.

Top news of the day from across the health care landscape.

Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.

A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.

Aspirin therapy found to improve liver function test results and survival after transarterial embolization for hepatocellular carcinoma.

Top news of the day from across the health care landscape.

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.